1980PubMedRequires access

[Possible indications for medroxyprogesterone in the management of breast cancer].

J Bonte

Open publisher page 0 citations

Abstract

There are several possible uses of medroxyprogesterone acetate in the treatment of breast cancer: 1) contraception by trimestral intramuscular injection of medroxyprogesterone acetate in a low dose of 50 mg. This form of treatment is better indicated for young women who desire contraception and who are affected by breast carcinoma in its early stages; 2) assisting hormonotherapy by average dose of medroxyprogesterone acetate, i.e. 1 g a week, in the treatment of breast cancer whenever auxillary ganglia have already been invaded by the neoplasm; this treatment supersedes chemotherapy treatment which has several uncomfortable side effects; and 3) hormonotherapy with high dose of medroxyprogesterone acetate, i.e., 1 g per diem, by intramuscular injection in the treatment of well established and metastatic breast cancer. This treatment yields positive results in about 45% of cases, but it often causes abcesses at the site of injection because of the high concentration. Increase in body weight often occompanies the treatment.

About this research paper

What this paper is about

There are several possible uses of medroxyprogesterone acetate in the treatment of breast cancer: 1) contraception by trimestral intramuscular injection of medroxyprogesterone acetate in a low dose of 50 mg. This form of treatment is better indicated for young women who desire contraception and who are affected by breast carcinoma in its early stages; 2) assisting hormonotherapy by average dose of medroxyprogesterone acetate, i.e. 1 g a week, in the treatment of breast cancer whenever auxillary ganglia have already been invaded by the neoplasm; this treatment supersedes chemotherapy treatment which has several uncomfortable side effects; and 3) hormonotherapy with high dose of medroxyprogesterone acetate, i.e., 1 g per diem, by intramuscular injection in the treatment of well established and metastatic breast cancer. This treatment yields positive results in about 45% of cases, but it often causes abcesses at the site of injection because of the high concentration. Increase in body weight often occompanies the treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

There are several possible uses of medroxyprogesterone acetate in the treatment of breast cancer: 1) contraception by trimestral intramuscular injection of medroxyprogesterone acetate in a low dose of 50 mg. This form of treatment is better indicated for young women who desire contraception and who are affected by breast carcinoma in its early stages; 2) assisting hormonotherapy by average dose of medroxyprogesterone acetate, i.e. 1 g a week, in the treatment of breast cancer whenever auxillary ganglia have already been invaded by the neoplasm; this treatment supersedes chemotherapy treatment which has several uncomfortable side effects; and 3) hormonotherapy with high dose of medroxyprogesterone acetate, i.e., 1 g per diem, by intramuscular injection in the treatment of well established and metastatic breast cancer. This treatment yields positive results in about 45% of cases, but it often causes abcesses at the site of injection because of the high concentration. Increase in body weight often occompanies the treatment.

Key concepts: Medroxyprogesterone acetate, Medroxyprogesterone, Medicine, Breast cancer, Intramuscular injection, Cancer, Gynecology, Mammary carcinoma

Related papers

Back to paper searchBrowse research topicsOriginal source
[Possible indications for medroxyprogesterone in the management of breast cancer]. — Research Paper | ScholarLens